156 related articles for article (PubMed ID: 20127014)
1. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma.
Tanuma J; Izumo T; Hirano M; Oyazato Y; Hori F; Umemura E; Shisa H; Hiai H; Kitano M
Oncol Rep; 2010 Mar; 23(3):739-44. PubMed ID: 20127014
[TBL] [Abstract][Full Text] [Related]
2. The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.
Ye Y; Shi Y; Zhou Y; Du C; Wang C; Zhan H; Zheng B; Cao X; Sun MH; Fu H
Ann Surg Oncol; 2010 Dec; 17(12):3354-61. PubMed ID: 20844967
[TBL] [Abstract][Full Text] [Related]
3. ECRG1 and FGFR4 single nucleotide polymorphism as predictive factors for nodal metastasis in oral squamous cell carcinoma.
Choi KY; Rho YS; Kwon KH; Chung EJ; Kim JH; Park IS; Lee DJ
Cancer Biomark; 2012-2013; 12(3):115-24. PubMed ID: 23481570
[TBL] [Abstract][Full Text] [Related]
4. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma.
da Costa Andrade VC; Parise O; Hors CP; de Melo Martins PC; Silva AP; Garicochea B
Exp Mol Pathol; 2007 Feb; 82(1):53-7. PubMed ID: 17084840
[TBL] [Abstract][Full Text] [Related]
5. FGFR4 Is a Potential Predictive Biomarker in Oral and Oropharyngeal Squamous Cell Carcinoma.
Koole K; van Kempen PM; van Bockel LW; Smets T; van der Klooster Z; Dutman AC; Peeters T; Koole R; van Diest P; van Es RJ; Willems SM
Pathobiology; 2015; 82(6):280-9. PubMed ID: 26551585
[TBL] [Abstract][Full Text] [Related]
6. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
[TBL] [Abstract][Full Text] [Related]
7. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor.
Frullanti E; Berking C; Harbeck N; Jézéquel P; Haugen A; Mawrin C; Parise O; Sasaki H; Tsuchiya N; Dragani TA
Eur J Cancer Prev; 2011 Jul; 20(4):340-7. PubMed ID: 21412156
[TBL] [Abstract][Full Text] [Related]
8. Role of TP53 in the progression of pre-malignant and malignant oral mucosal lesions. A follow-up study of 144 patients.
Ogmundsdóttir HM; Björnsson J; Holbrook WP
J Oral Pathol Med; 2009 Aug; 38(7):565-71. PubMed ID: 19473450
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma.
Streit S; Bange J; Fichtner A; Ihrler S; Issing W; Ullrich A
Int J Cancer; 2004 Aug; 111(2):213-7. PubMed ID: 15197773
[TBL] [Abstract][Full Text] [Related]
10. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer.
Spinola M; Leoni VP; Tanuma J; Pettinicchio A; Frattini M; Signoroni S; Agresti R; Giovanazzi R; Pilotti S; Bertario L; Ravagnani F; Dragani TA
Oncol Rep; 2005 Aug; 14(2):415-9. PubMed ID: 16012724
[TBL] [Abstract][Full Text] [Related]
11. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.
Falvella FS; Frullanti E; Galvan A; Spinola M; Noci S; De Cecco L; Nosotti M; Santambrogio L; Incarbone M; Alloisio M; Calabrò E; Pastorino U; Skaug V; Haugen A; Taioli E; Dragani TA
Int J Cancer; 2009 Jun; 124(12):2880-5. PubMed ID: 19296538
[TBL] [Abstract][Full Text] [Related]
12. Association between the TP53 codon72 polymorphism and oral cancer risk and prognosis.
Kuroda Y; Nakao H; Ikemura K; Katoh T
Oral Oncol; 2007 Nov; 43(10):1043-8. PubMed ID: 17306604
[TBL] [Abstract][Full Text] [Related]
13. Functional -1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users.
Tu HF; Wu CH; Kao SY; Liu CJ; Liu TY; Lui MT
J Oral Pathol Med; 2007 Aug; 36(7):409-14. PubMed ID: 17617834
[TBL] [Abstract][Full Text] [Related]
14. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients.
Spinola M; Leoni V; Pignatiello C; Conti B; Ravagnani F; Pastorino U; Dragani TA
J Clin Oncol; 2005 Oct; 23(29):7307-11. PubMed ID: 16061909
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Significance of FGFR4 Gly388 Polymorphism in Esophageal Squamous Cell Carcinoma after Concurrent Chemoradiotherapy.
Shim HJ; Shin MH; Kim HN; Kim JH; Hwang JE; Bae WK; Chung IJ; Cho SH
Cancer Res Treat; 2016 Jan; 48(1):71-9. PubMed ID: 25989802
[TBL] [Abstract][Full Text] [Related]
16. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis.
Yang YC; Lu ML; Rao JY; Wallerand H; Cai L; Cao W; Pantuck A; Dalbagni G; Reuter V; Figlin RA; Belldegrun A; Cordon-Cardo C; Zhang ZF
Br J Cancer; 2006 Dec; 95(11):1455-8. PubMed ID: 17088904
[TBL] [Abstract][Full Text] [Related]
17. FGFR4 profile as a prognostic marker in squamous cell carcinoma of the mouth and oropharynx.
Dutra RL; de Carvalho MB; Dos Santos M; Mercante AM; Gazito D; de Cicco R; Group G; Tajara EH; Louro ID; da Silva AM
PLoS One; 2012; 7(11):e50747. PubMed ID: 23226373
[TBL] [Abstract][Full Text] [Related]
18.
Cho SH; Hong CS; Kim HN; Shin MH; Kim KR; Shim HJ; Hwang JE; Bae WK; Chung IJ
Cancer Res Treat; 2017 Jul; 49(3):766-777. PubMed ID: 27857023
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal study of TP53 mutations in eight patients with potentially malignant oral mucosal disorders.
Ogmundsdóttir HM; Hilmarsdóttir H; Björnsson J; Holbrook WP
J Oral Pathol Med; 2009 Oct; 38(9):716-21. PubMed ID: 19473449
[TBL] [Abstract][Full Text] [Related]
20. Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status.
Fallai C; Perrone F; Licitra L; Pilotti S; Locati L; Bossi P; Orlandi E; Palazzi M; Olmi P
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1053-9. PubMed ID: 19577857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
